SAN DIEGO -- Aldevron announced today from the floor of the Festival of Biologics in San Diego, its expansion plans for its Freiburg, Germany facility. The Freiburg location houses the GENOVAC antibody development platform and became the second site for Aldevron in 2004.
Aldevron is exhibiting at the CAR-TCR Summit in London February 25 – 27, 2019, and was excited to share the news of our partnership with Oxford Genetics to produce lentivirus. Click here to read the interview with James Brown, Aldevron’s Vice President of Corporate Development about the collaboration.
Keleigh Pearson has joined Aldevron as its new corporate attorney. In her position, Pearson will serve as in-house legal counsel for business transactions including negotiation, drafting, and review of contracts, as well as an advisor for corporate governance and operations.
Novel Packaging and Expression Plasmids Promise to Reduce Gene Therapy Manufacturing Costs and Delivery Times
Miami, FL - Aldevron announced from Phacilitate Leaders World in Miami the immediate availability of standardized plasmids for lentiviral production through a license agreement with Oxford Genetics.
Agreement provides Sarepta with committed capacity and dedicated manufacturing slots for GMP-grade plasmid production for its micro-dystrophin Duchenne muscular dystrophy (DMD) gene therapy program, as well as plasmid capacity for future gene therapy programs
Cambridge, Mass., January 2, 2019 - Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases and Aldevron, the leading producer of custom nucleic acids, proteins, and antibodies for the biotechnology industry, announced today that they have entered into a long-term strategic relationship for the supply of plasmid DNA to fulfill Sarepta’s needs for its gene therapy clinical trials and commercial supply.
Girl saved by gene therapy will speak at Breakthrough Symposium featuring leading biotechnology researchers
This article was originally published in the October 26, 2018, edition of The Forum of Fargo-Moorhead and is republished here in its entirety.
Michael Chambers, Founder and CEO, Among 100 Most Intriguing Entrepreneurs at 2018 Builders + Innovators Summit
Goldman Sachs (NYSE:GS) is recognizing Aldevron CEO and Founder Michael Chambers as one of the 100 Most Intriguing Entrepreneurs at the 2018 Builders + Innovators Summit in Santa Barbara, California.
Newly manufactured plasmids will be applied in clinical trials evaluating Oncoprex in combination with targeted therapies and immunotherapies
Austin, Texas, Cambridge, Mass. and Fargo, N.D. – September 26, 2018 – Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has signed an agreement with Aldevron, a leading contract manufacturing organization, to supply TUSC2 (Tumor Suppressor Candidate2) plasmid DNA for use in Genprex’s clinical development program evaluating its immunogene therapy Oncoprex for the treatment of non-small cell lung cancer.
Is Aldevron Fargo's next Microsoft? Homegrown biotechnology firm continues to grow, attracts major investor
This article was originally published in the September 23, 2018, edition of The Forum of Fargo-Moorhead and is republished here in its entirety.
Aldevron has expanded its leadership team by appointing Mike Busch as Vice President of Human Resources.